Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Anti-Cancer Drugs

• Publication date

  2003-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001813-200304000-00009PMID 12679736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer.

  2002cited by this paper
• Present and future treatment of pancreatic cancer.

  2002cited by this paper
• ZD1839 (Iressa): what's in it for the patient?

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Pancreatic cancer: who benefits from curative resection?

  2002cited by this paper
• Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies

  2001cited by this paper
• Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells

  2001cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

  2000cited by this paper
• Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors

  1999cited by this paper
• Prognosis of human pancreatic adenocarcinoma: review of clinical and histopathological variables and possible uses of new molecular methods.

  1999cited by this paper
• Dextran Polymer Conjugate Two-Step Visualization System for Immunohistochemistry: A Comparison of EnVision+ With Two Three-Step Avidin-Biotin Techniques

  1998cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1.

  1997cited by this paper
• Growth stimulation of colorectal carcinoma cells via the c‐kit receptor is inhibited by TGF‐β1

  1997cited by this paper
• Coexpression of the c-kit and stem cell factor genes in breast carcinomas.

  1995cited by this paper
• Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group.

  1994cited by this paper
• Antigen unmasking on formalin‐fixed, paraffin‐embedded tissue sections

  1993cited by this paper
• Expression of c-kit and kit ligand in human colon carcinoma cells.

  1993cited by this paper
• Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues.

  1993cited by this paper
• Monoclonal antibody YB5.B8 identifies the human c-kit protein product.

  1991cited by this paper
• Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors.

  1991cited by this paper
• The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype

  1991cited by this paper
• Monoclonal antibody YB5.B8 identifies the human c-kit protein product

  1991cited by this paper
• The kit ligand: a cell surface molecule altered in steel mutant fibroblasts.

  1990cited by this paper
• Steel locus defines new multipotent growth factor.

  1990cited by this paper
• c-kit protein, a transmembrane kinase: identification in tissues and characterization

  1988cited by this paper
• Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus.

  1988cited by this paper
• The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene.

  1988cited by this paper
• The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus

  1988cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper
• A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family

  1986cited by this paper

• Expression and Purification of Human Stem Cell Factor and Its Effect on the Growth of A549 Cells

  2025cites this paper
• Desmoplastic Adamantinoma-like Thymic Carcinoma

  2022cites this paper
• Immunohistochemical study of C-kit expression in subtypes of renal cell carcinoma.

  2018cites this paper
• Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma

  2014cites this paper
• Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.

  2013cites this paper
• Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer

  2011cites this paper
• Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

  2011cites this paper
• Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1α under normoxic condition.

  2011cites this paper
• Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells

  2010cites this paper
• Expression of L1CAM, COX‐2, EGFR, c‐KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?

  2010cites this paper
• Molecular Signaling Pathways in Pancreatic Cancer

  2008cites this paper
• A Phase II Trial of Imatinib Mesylate in Patients With Metastatic Pancreatic Cancer

  2008cites this paper
• CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid.

  2008cites this paper
• MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.

  2008cites this paper
• CD117/KIT Expression in Pancreatic Adenocarcinoma

  2008cites this paper
• Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models

  2007cites this paper
• Analysis of c-kit protein expression in pancreatic neoplasms and its implication for prognosis.

  2007cites this paper
• Emerging Role of Platelet-Derived Growth Factor Receptor-β Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer

  2007cites this paper
• An Unusual Case of Undifferentiated Carcinoma in situ With Osteoclast-like Giant Cells of the Pancreas

  2006cites this paper
• The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.

  2006cites this paper
• The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells

  2006cites this paper
• A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas

  2004cites this paper
• Successful Treatment with Imatinib Mesylate of a Gastrointestinal Stromal Tumor with c-kit exon 11 Mutation

  2004cites this paper
• Imatinib mesylate (STI571; Glivec)—a new approach in the treatment of biliary tract cancer?

  2003cites this paper